Skip to main content
. 2022 Jun 10;56(5):689–697. doi: 10.1007/s43441-022-00422-z

Table 7.

CDxs targeting KRAS wild-type mutation for colorectal cancer

FDA-approved companion diagnostic FDA-approved therapeutic products
Erbitux® (cetuximab) Vectibix® (panitumumab)
FoundationOne CDx x x
Praxis extended RAS panel x
Cobas KRAS mutation test x x
Therascreen KRAS RGQ PCR KIT x x
Onco/Reveal Dx Lung & colon cancer assay x x